Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor

Journal of Biological Response Modifiers

Volumn 9, Issue 4, 1990, Pages 431-438

  Skornick, Yehudah ^a   Topalian, Suzanne ^a   Rosenberg, Steven A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Draining lymph nodes; Human tumors; Immunotherapy; Peripheral blood lymphocytes; Tumor infiltrating lymphocytes

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOCHEMISTRY; HUMAN; HUMAN CELL; LYMPH NODE CELL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; CELL DIVISION; CELLS, CULTURED; COMPARATIVE STUDY; CULTURE MEDIA; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; HUMAN; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTES; MALE; MIDDLE AGE; NEOPLASMS; PHENOTYPE;

EID: 0025040280     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1318.
2. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 1987; 79: 1067.
3. Belldegrun A, Muul LM, Rosenberg SA. Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988; 48: 206.
4. Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 1987; 47: 6353.
5. Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986; 46: 3011.
6. Kradin RL, Boyle LA, Preffer FI, et al. Tumor-derived in-terleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987; 24: 76.
7. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38: 367.
8. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989.
9. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127.
10. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6: 839.
11. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714.
12. Rosenberg SA, Packard B, Aebersold PM, et al. Immunotherapy of patients with metastatic melanoma using tumor infiltrating lymphocytes and interleukin-2: preliminary report. N Engl J Med 1988; 319: 1676.
13. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485.
14. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology 1986. Philadelphia: J. B. Lippincott, 1986: 55.
15. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889.
16. Cozzolino F, Torcia M, Carossino AM, et al. Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumor-specific lym-phoproliferative response. J Exp Med 1987; 166: 303.
17. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 1987; 139: 295.
18. Slingluff CL, Darrow TL, Seigler HF. Human T cells specifically activated against autologous malignant melanoma. Arch Surg 1987; 122: 1407.
19. Slingluff CL, Darrow T, Vervaert C, Quinn-Allen MA, Seigler HF. Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. JNCI 1988; 80: 1016.
20. Stephenson KR, Perry-Lalley D, Shu S, Chang AE. Role of regional lymph nodes in the development of tumor immunity. Surg Forum 1987; 38: 438.
21. Vose BM, Vanky F, Klein E. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer 1977; 20: 895.